Pe. Keck et al., NEUROLEPTIC MALIGNANT SYNDROME AND MALIGNANT HYPERTHERMIA - END OF A CONTROVERSY, The Journal of neuropsychiatry and clinical neurosciences, 7(2), 1995, pp. 135-144
Two primary hypotheses have been proposed to explain the pathophysiolo
gy of the neuroleptic malignant syndrome (NMS): 1) that NMS is produce
d by abrupt and extensive central dopamine receptor blockade by neurol
eptics, particularly in nigrostriatal and hypothalamic pathways; and 2
) that NMS, like malignant hyperthermia (MH), results fi om a preexist
ing defect in skeletal muscle metabolism that is unmasked or provoked
by neuroleptic exposure. To evaluate these models, the authors review
studies published since 1980 of the clinical features, epidemiology, r
isk factors, laboratory assessment, and relevant animal models of NMS
and MH. Data from these studies suggest that although NMS and MH are c
linically similar, they are pharmacologically distinct, implying that
cross-reactivity between triggering agents is unlikely to occur.